Foram encontradas 7.654 questões

Resolva questões gratuitamente!

Junte-se a mais de 4 milhões de concurseiros!

www.qconcursos.com
Q2242070
Administração Financeira e Orçamentária Programação Orçamentária e Financeira , Descentralização de Créditos Orçamentários e Recursos Financeiros em AFO ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242070 Administração Financeira e Orçamentária
A autorização de uma unidade orçamentária a uma unidade administrativa subordinada processar despesas orçamentárias denomina-se 
Alternativas
Q2242069
Administração Financeira e Orçamentária Programação Orçamentária e Financeira , Descentralização de Créditos Orçamentários e Recursos Financeiros em AFO ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242069 Administração Financeira e Orçamentária
A descentralização de recursos financeiros processa-se a partir
Alternativas
Q2242068
Administração Financeira e Orçamentária Créditos Adicionais ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242068 Administração Financeira e Orçamentária
A soma do excesso de arrecadação que constou do balanço orçamentário do exercício foi de 50, incluindo excessos às operações de crédito autorizadas para créditos adicionais especiais, no valor de 10 e 10 de fundo especial aplicado nas respectivas despesas do exercício. No exercício também foi aberto um crédito extraordinário no valor de 10. Assim, o excesso de arrecadação que poderia ter sido utilizado nesse exercício seria de
Alternativas
Q2242067
Administração Financeira e Orçamentária Créditos Adicionais ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242067 Administração Financeira e Orçamentária
Há dispensa de prévia autorização legislativa para a abertura por decreto-executivo ou por medida provisória, em se tratando de crédito
Alternativas
Q2242066
Administração Financeira e Orçamentária Estágios da Receita e Despesa , Estágios da Despesa Orçamentária , Etapas da Despesa ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242066 Administração Financeira e Orçamentária
Tendo por base os títulos e documentos comprobatórios do respectivo crédito, a liquidação da despesa objetiva a
Alternativas
Q2242065
Administração Financeira e Orçamentária Estágios da Receita e Despesa , Estágios da Despesa Orçamentária , Etapas da Despesa ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242065 Administração Financeira e Orçamentária
O empenho é conceituado legalmente como ato emanado da autoridade competente que cria para o Estado obrigação de pagamento pendente ou não de implemento de condição dele defluindo. A emissão da nota de empenho dele deflui e indica: o credor, a especificação e importância da despesa, bem como a posição do respectivo crédito orçamentário, excetuados os casos de pronto pagamento em regime de adiantamento. O empenho se consuma com a
Alternativas
Q2242063
Administração Financeira e Orçamentária Orçamento Público em AFO , Instrumentos de Planejamento ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242063 Administração Financeira e Orçamentária
Em sua concepção, aproxima-se do planejamento operacional
Alternativas
Q2242062
Administração Financeira e Orçamentária Orçamento Público em AFO , Introdução ao Orçamento Público ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242062 Administração Financeira e Orçamentária
A elaboração do orçamento, objetivando uma ação integrada, articulada e racional, processa-se
Alternativas
Q2242061
Administração Financeira e Orçamentária Orçamento Público em AFO , Finanças Públicas e Orçamento de acordo com a CF/88 ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242061 Administração Financeira e Orçamentária
A Constituição Federal, ao estabelecer que os recursos que, em decorrência de veto, emenda ou rejeição do projeto de lei orçamentária anual, ficarem sem despesas correspondentes, poderão ser utilizados, conforme o caso, mediante créditos especiais ou suplementares, com prévia e específica autorização legislativa, refere-se à destinação dos recursos
Alternativas
Q2242060
Direito Financeiro Atividade Financeira do Estado e Sistema Financeiro Nacional - SFN ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242060 Direito Financeiro
A legislação de normas de Direito Financeiro que referenciou ordenadores de despesas de forma ampla e específica é
Alternativas
Q2242059
Administração Financeira e Orçamentária Créditos Adicionais , Programação Orçamentária e Financeira , Decreto Sobre a Programação Orçamentária e Financeira - Lei 4.320 de 1964 ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242059 Administração Financeira e Orçamentária
A diferença positiva apurada no fim do exercício financeiro entre as disponibilidades acrescidas dos realizáveis financeiros e a dívida flutuante, subtraídos os créditos transferidos do período anterior e adicionadas as operações de crédito a realizar vinculadas a esses créditos transferidos, vem a ser o
Alternativas
Q2242058
Administração Financeira e Orçamentária Restos a Pagar ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242058 Administração Financeira e Orçamentária
    Uma entidade de direito público apresentou no encerramento do exercício os seguintes valores: Créditos Fixados no orçamento 120, Créditos Adicionais Abertos 30, Créditos Anulados 5, Economia Orçamentária 15, Despesa Liquidada Paga 90, Despesa Liquidada a Pagar 30, Despesa Paga 90.
 O valor dos restos a pagar não processados foi de:
Alternativas
Q2242057
Administração Financeira e Orçamentária Restos a Pagar ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242057 Administração Financeira e Orçamentária
    Uma entidade de direito público apresentou no encerramento do exercício os seguintes valores: Créditos Fixados no orçamento 120, Créditos Adicionais Abertos 30, Créditos Anulados 5, Economia Orçamentária 15, Despesa Liquidada Paga 90, Despesa Liquidada a Pagar 30, Despesa Paga 90.
O total dos restos a pagar apurados no encerramento do exercício foi de:
Alternativas
Q2242052
Administração Financeira e Orçamentária Legislação Complementar de AFO , SIAFI ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242052 Administração Financeira e Orçamentária
O Sistema Integrado de Administração Financeira do Governo Federal – Siafi, NÃO tem como um de seus objetivos permitir
Alternativas
Q2242050
Auditoria Testes, Procedimentos e Técnicas de Auditoria , Testes em Áreas Específicas das Demonstrações Contábeis ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242050 Auditoria
 O auditor da CVM, ao analisar as demonstrações financeiras de uma companhia aberta, constatou que esta havia adquirido debêntures de sua própria emissão. Com relação às condições deste tipo de operação, está de acordo com os dispositivos da Lei nº 6.404/76:
Alternativas
Q2242049
Auditoria Testes, Procedimentos e Técnicas de Auditoria , Processamento Eletrônico de Dados (PED) ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242049 Auditoria
No programa de auditoria para exames dos sistemas de PED, o auditor NÃO deverá considerar o exame 
Alternativas
Q2242048
Auditoria Normas de Auditoria , Considerações de Leis e Regulamentos na Auditoria ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242048 Auditoria
O auditor da CVM, ao efetuar fiscalização nas demonstrações financeiras do Banco Depósito S.A., constatou que o auditor responsável pelas demonstrações contábeis, objeto da fiscalização, possui parentesco em primeiro grau com o contador da empresa auditada. Nesse caso, para atender à Lei nº 6.404/76 e às normas da CVM, os trabalhos de auditoria serão considerados:
Alternativas
Q2241614
Inglês Interpretação de texto | Reading comprehension ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Sistemas |
Q2241614 Inglês
The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....58.... Sweden now seems in the best position to capture a $25 billion market.

    Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or an activity that could eventually lead to human cloning.

    Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

    Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

     Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

    One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
   
   Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

    Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

    The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

     If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
According to the text,
Alternativas
Q2241612
Inglês Interpretação de texto | Reading comprehension ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Sistemas |
Q2241612 Inglês
The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....58.... Sweden now seems in the best position to capture a $25 billion market.

    Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or an activity that could eventually lead to human cloning.

    Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

    Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

     Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

    One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
   
   Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

    Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

    The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

     If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
Segundo o texto, a NeuroNova
Alternativas
Q2241608
Inglês Sinônimos | Synonyms ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Sistemas |
Q2241608 Inglês
The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ....58.... Sweden now seems in the best position to capture a $25 billion market.

    Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....59.... methods are morally wrong. They are ....60.... a form of abortion or an activity that could eventually lead to human cloning.

    Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

    Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

     Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

    One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
   
   Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

    Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

    The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

     If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)
A synonym for odd would be: 
Alternativas
Respostas
7561: B
7562: D
7563: B
7564: D
7565: C
7566: A
7567: C
7568: B
7569: C
7570: B
7571: D
7572: A
7573: D
7574: D
7575: E
7576: E
7577: E
7578: D
7579: E
7580: E
www.qconcursos.com